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Activation of platelets by the serine protease thrombin is a critical event in haemostasis. This process involves
the binding of thrombin to glycoprotein Ibα (GpIbα) and cleavage of protease-activated receptors (PARs).
The N-terminal extracellular domain of GpIbα contains an acidic peptide stretch that has been identified as the
main thrombin binding site, and both anion binding exosites of thrombin have been implicated in GpIbα
binding, but it remains unclear how they are involved. This issue is of critical importance for the mechanism of
platelet activation by thrombin. If both exosites bind to GpIbα, thrombin could potentially act as a platelet
adhesion molecule or receptor dimerisation trigger. Alternatively, if only a single site is involved, GpIbα may
serve as a cofactor for PAR-1 activation by thrombin. To determine the involvement of thrombin's two exosites
in GpIbα binding, we employed the complementary methods of mutational analysis, binding studies, X-ray
crystallography and NMR spectroscopy. Our results indicate that the peptide corresponding to the C-terminal
portion of GpIbα and the entire extracellular domain bind exclusively to thrombin's exosite II. The interaction
of thrombin with GpIbα thus serves to recruit thrombin activity to the platelet surface while leaving exosite I free
for PAR-1 recognition.
© 2013 The Authors. Published by Elsevier Ltd. All rights reserved.Introduction
Thrombin is the final protease of the coagulation
cascade [1,2], and its activity is crucial for the formation
of stable blood clots [3]. In addition to the cleavage
of fibrinogen to fibrin, thrombin also feeds back to
upregulate its own production by activating cofactors
fV and fVIII, the protease fXI, and through cleavage of
the protease-activated receptor (PAR)-1 [4,5]. PAR-1
is a seven-transmembraneG-protein-coupled receptor
expressed on the surface of platelets. Upon cleavage
of the N-terminal extracellular peptide at Arg41,
the newly formed N-terminus inserts into the body
of the receptor triggering platelet activation. The rate of
platelet PAR-1 cleavage by thrombin is increased by
approximately 5-fold in the presence of glycoprotein
Ibα (GpIbα) [6], a member of the platelet GpIb-IX-V
receptor complex [7], that has been identified as the
high-affinity receptor for thrombin on the surface of
platelets [8]. The crystal structure of the extracellularatter © 2013 The Authors. Published by Elsdomain of GpIbα, composed of the 300 N-terminal
residues, revealed an elongated banana-like
shape dominated by a leucine-rich repeat (LRR)
region, followed by a flexible acidic stretch at the
very C-terminus (Gly271–Glu282) containing three
sulfated tyrosine residues (276, 278 and 279) [9].
The acidic residues in this region and the posttrans-
lational sulfation of the tyrosines are crucial for binding
of GpIbα to thrombin [10–12].
Thrombin has two anion binding exosites, both
of which are essential for its activity and specificity
(Fig. 1a and b) [13]. Exosite I is the fibrinogen
recognition exosite, but it also interacts with a variety
of other substrates, cofactors and inhibitors, including
the N-terminal region of PAR-1, the cofactor thrombo-
modulin (TM; shown in Fig. 1a and b) and the
C-terminal peptide of the inhibitor hirudin (known
as hirugen). Exosite II binds to glycosaminoglycans
such as heparin (shown in Fig. 1a and b), to the γ′-chain
of fibrinogen and to the second kringle domainevier Ltd. All rights reserved. J. Mol. Biol. (2014) 426, 881–893
a)
exosite I
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1OOK 1P8V
Fig. 1. Structure of thrombin and its exosite interactions with GpIbα. (a) A ribbon diagram of thrombin (heavy chain only)
is shown in the standard orientation coloured from its N-terminus to its C-terminus, from blue to red. In magenta are classic
exosite binding ligands, TM as ribbons (exosite I) and heparin as sticks (exosite II). The anion binding exosites are indicated.
(b) Thrombin is oriented as in (a) but shown in surface representation coloured according to electrostatic potential, with blue
positive and red negative. The active-site cleft is the deep red pocket between the exosites. (c) The crystal structure 1OOK is
shown, with thrombin in cyan and the acidic C-terminal region of GpIbα as magenta sticks. The chosen asymmetric unit
contained the copy of GpIbα shown binding to exosite I (right); however, a crystallographically related copy binds to exosite II
(left). (d) The crystal structure 1P8V is shown with thrombin in magenta and GpIbα in green. The acidic C-terminal region
(green sticks) binds only to exosite II, and exosite I is occupied by the LRR region (green ribbons) of a symmetry-relatedGpIbα
molecule.
882 GPIbα Interaction with Thrombinof prothrombin, known as fragment-2 (F2). Although
both exosite I and exosite II interactions are mediated
by electrostatics, there is a surprising degree of exosite
selectivity, with ligands often binding exclusively to one
site or the other [13]. At high concentrations, however,
there is evidence that some ligands, such as heparin,
can interact with both sites [14,15], although this is not
thought to be of physiological relevance. It has been
demonstrated that the two exosites can bind inde-
pendently and simultaneously to different ligands; for
example, when hirugen is bound to exosite I, GpIbα or
fibrinogen γ′ peptides are still able to bind to exosite II
[16]. However, particularly in the absence of active-site
occupation, there is a considerable degree of allosteric
communication between exosites I and II, with binding
at one exosite decreasing affinity of ligands for the
other [17].How thrombin binds to GpIbα has been studied
extensively for the last 30 years; however, the issue
remains unresolved. Initial experiments by cross-
linking thrombin to washed platelets showed that
the interaction was inhibited by addition of hirugen,
suggesting exosite-I-mediated interactions [18].
Other exosite I ligands such as TM or fibrin(ogen)
were also shown to block interactions between
GpIbα and thrombin [19]. In addition, the exosite-I-
deficient autolysis product γ-thrombin did not
appear to interact with GpIbα [18]. However, the
experiments with fibrinogen and hirugen could not
be reproduced by other groups, and subsequent
studies showed that GpIbα binding was not blocked
by the PAR-1 peptide or the exosite-I-specific
aptamer HD1 [20–22]. Originally, these contradic-
ting results were explained by binding of the various
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Fig. 2. Steady-state binding curves of thrombin to exosite
ligands. The binding of PAR-1 peptide (a), F2 (b) and the
acidic GpIbα peptide (c) to S195A thrombin (●), and S915A
thrombin with additional mutations R73E (■) and R93E (▲)
were assessed by plotting steady-state responses against
thrombin concentration. Dissociation constants were
calculated as indicated in Materials and Methods. Linear
or low magnitude responses are indicative of weak binding.
Table 1.Dissociation constants (μM) for thrombin andexosite
variants
Control R73E R93E
PAR-1 5.44 ± 1.76 N70 11.86 ± 1.52
Fragment-2 0.77 ± 0.17 1.88 ± 0.16 N100
GpIbα 1.03 ± 0.05 5.63 ± 0.69 N1000
883GPIbα Interaction with Thrombinpeptides to different subsites of thrombin's exosite I
[19]. Crystal structures, however, showed that fibrin-
ogen, TM, hirugen and PAR-1 cover similar regions
of exosite I [23–26]. Arguing against the involvement
of exosite I, mutations within the exosite (Arg67Ala,
Arg73Glu or Arg77aGlu; chymotrypsin numbering
scheme used throughout) were shown not to affect
GpIbα binding, and addition of a GpIbα acidic region
peptide did not inhibit the exosite-I-mediated activa-
tion of the PAR-1 peptide [19,22,27]. Consistent
with these results, several experiments supportedexclusive binding of GpIbα to exosite II. Binding was
completely abolished by ligands such as fibrinogen
γ′-peptide, heparin and the exosite-II-specific aptamer
HD22 and by chemical modification of exosite II [20–
22,28–30]. Mutations in exosite II were also shown
to weaken binding to GpIbα [22,27]. The biggest
effects were observed for mutations at Arg93, Arg233
and Lys236. Recent biophysical studies, including
H/D (hydrogen/deuterium) exchange, showed that
the binding of the acidic GpIbα peptide to thrombin
resembled fibrinogen γ′-peptide binding and was
different from the effects of hirugen, implying inter-
actions with exosite II, but not exosite I [31]. Other
researchers found an exosite II interaction in solution
but suggested a different binding mode involving both
exosites on surfaces, such as surface plasmon
resonance (SPR) sensor chips [32].
In 2003, two crystal structures of the GpIbα–
thrombin complex were published (1OOK and 1P8V)
(Fig. 1c and d) [33,34]. The structures were of similar
GpIbα constructswith twoof the three tyrosine residues
sulfated, and crystals were obtained after purifying a
1:1 GpIbα–thrombin complex by size-exclusion chro-
matography. Both crystals contained a single complex
in the asymmetric unit and had contacts between
crystallographically related GpIbα molecules in both
exosites of thrombin (Fig. 1c and d). In 1OOK, themost
intimate complex was chosen as the asymmetric unit in
spite of the fact that it had no interactionswith exosite II.
The total contact surface area of the complex was
2120 Å2, with less than half contributed by the acidic
C-terminal region. A symmetry-related molecule of
GpIbα buried a total of 1093 Å2 but had a larger total
contact surface for the acidic region (1046.7 versus
1007.9 Å2). Both exosite contacts are thus plausible,
and both involve the acidic C-terminal region (Fig. 1c).
In 1P8V, the asymmetric unit again was chosen based
on the most intimate complex (1867.6 Å2), but this
time, it involved exosite II. A symmetry-related GpIbα
molecule buried 1408.2 Å2 and contacted exosite I.
However, this exosite I interaction did not involve the
acidic region of GpIbα; rather, the LRR region bound
towards the “top” of the exosite (Fig. 1d). The authors of
both papers concluded that the bivalent contacts
observed in their crystals would require thrombin to
bind to two separate GpIbα molecules as seen in the
crystal contacts. It was hypothesised that interactions
with thrombin would effectively cross-link GpIbα
molecules and their associated complexes together,
either on the same or adjacent platelets.
Table 2.Crystals, data processing, refinement and models
Low salt High salt
Crystal
Space group C2 P21
Cell dimensions
a, b, c (Å) 149.57, 50.56,
76.28
74.22, 51.33,
150.08
β (°) 96.13 96.13
Solvent content (%) 37.3 36.9
Data processing statistics
Wavelength (Å) 0.80 0.80
Resolution (Å) 1.60 (1.69–1.60) 1.75 (1.84–1.75)
Total reflections 182,431 275,332
Unique reflections 72,363 105,859
〈I/σ(I)〉 9.6 (1.8) 9.2 (1.7)
Completeness (%) 96.8 (98.4) 93.2 (95.8)
Multiplicity 2.5 (2.5) 2.6 (2.4)
Rmerge 0.075 (0.504) 0.056 (0.448)
Model
Number of
protein/other atoms
4680/727 8857/700
Mean B-factor (Å2) 10.3 17.3
Refinement statistics
Reflections in
working/free set
68,655/3646 100,532/5305
R-factor/Rfree 15.45/18.73 20.95/24.23
RMSD of bonds (Å)/angles
(°) from ideality
0.020/2.07 0.017/1.80
Ramachandran plota (%)
Favoured 97.5 97.7
Outlier 0.0 0.09
a Calculated using MolProbity [36].
884 GPIbα Interaction with ThrombinIt is clear from biochemical and structural studies
that exosite II is involved, and most agree that it
is the principal high-affinity interaction. However,
the possibility of an additional exosite I interaction
has been supported by multiple biochemical and
structural studies and has important implications
for the function of thrombin on platelets. The goal
of this study is to determine if exosite I of thrombin
is involved in GpIbα binding by employing comple-
mentary methods of mutagenesis, binding studies,
X-ray crystallography and NMR spectroscopy.
These methods allowed us to obtain a detailed
picture of the interactions between thrombin and
GpIbα and show that, even at high concentrations or
on a surface, GpIbα binds exclusively to thrombin's
exosite II. On platelets, this would leave exosite I free
to recognise PAR-1 and other substrates, such as
fibrinogen.Results
Binding of thrombin variants to the
GpIbα peptide
In order to determine the binding site of the GpIbα
acidic region on thrombin, we performed studiesusing a fortéBIO Octet Red instrument. This
technology uses biolayer interferometry to monitor
ligand binding to proteins or peptides immobilised onto
glass fibre tips. Measurements are taken in 96-well
plates, with results generally comparable to SPR [35].
We fixed biotinylated peptides onto streptavidin
sensor tips and monitored binding of S195A thrombin
at various concentrations. Dissociation constants
were determined by plotting steady-state response
versus thrombin concentration (Fig. 2 and Table 1).
The importance of the two exosites was tested by
creating charge reversal mutations within exosites I
and II, Arg73Glu and Arg93Glu, respectively. These
residues have been shown by crystallographic and
mutagenesis studies to be important for ligand binding
at the two exosites [13]. The exosite-I-specific PAR-1
peptide (Fig. 2a) and exosite-II-specific ligand F2
(Fig. 2b) were used as controls. As expected, thrombin
bound to the PAR-1 peptide with moderate affinity
(Kd of 5.44 ± 1.76 μM). The exosite II mutation had
a small effect on binding (Kd of 11.86 ± 1.52 μM),
possibly due to the altered electrostatics of the protein
surface or allosteric effects of the mutation. The
exosite I mutation resulted in a linear response with
no sign of saturation even at high thrombin concen-
trations, and we were able only to get a poor estimate
of Kd for PAR-1 binding to this mutant. The effect
of mutations on the exosite-II-specific ligand F2 also
yielded the expected results. The affinity of thrombin
for F2 (Kd of 0.77 ± 0.17 μM)wasonly slightly affected
by the exosite I mutation (Kd of 1.88 ± 0.16 μM),
consistent with what was observed with the PAR-1
peptide, whereas the exosite II mutation had a
profound effect on binding. After these successful
control experiments, we tested the binding of a GpIbα
peptide corresponding to Gly268–Thr284, with all
three tyrosine residues phosphorylated, mimicking
the naturally occurring sulfotyrosines. The exosite I
mutation weakened the affinity for the GpIbα peptide
(Kd from 1.03 ± 0.05 μM to 5.63 ± 0.69 μM) in line
with what was observed for the control ligands,
whereas the exosite II mutation resulted in a lack
of saturation of signal, even when higher thrombin
concentrations were used (up to 40 μM). Taken
together, these results suggest that the acidic C-
terminal GpIbα peptide binds to thrombin's exosite II
with a similar degree of “specificity” as F2, the
quintessential exosite II ligand.
Crystal structures of the thrombin–GpIbα
peptide complex
To determine how the acidic GpIbα peptide binds
to thrombin when in excess and unconstrained
by the LRR region, we established crystal trials
with a 10-fold molar excess of peptide over thrombin
inhibited with D-phenylalanyl-L-prolyl-L-arginine
chloromethyl ketone (PPACK). PPACK reduces
thrombin's flexibility and thus PPACK-thrombin has
a) b)
c) d)
Fig. 3. Crystal structure of the acidic GpIbα peptide bound to thrombin. All panels are from the low-salt structure.
(a) Thrombin is shown in cartoon representation with the GpIbα peptides in magenta and PPACK as yellow sticks.
The 2Fo − Fc electron density for the peptide (contoured at 1× theRMSDof themap) is shown as bluemesh. (b) A close-up of
the electron density is shown in stereo. (c) Detail of the binding site with GpIbα residues labelled in red and thrombin side
chains interacting with the ligand are shown as sticks and labelled black. (d) Thrombin's exosite II is shown in surface
representation and coloured according to the electrostatic potential with the GpIbα peptide as magenta sticks.
885GPIbα Interaction with Thrombinbetter crystallisation properties than apo-thrombin.
Diffraction quality crystals grew in two space groups,
C2 and P21, with two and four copies of thrombin
in the asymmetric units, respectively. The first crystal
grew in 50 mM sodium formate (“low salt”) and
diffracted to 1.60 Å. The structure is of high quality
and was refined to final Rwork/Rfree of 15.45/18.73%
(full crystallographic statistics are reported in
Table 2). The asymmetric unit contains two nearly
identical thrombin molecules with a Cα RMSD of
0.486 Å (residues 1c–14j, 16–147 and 150–246)
and only small differences in the N-terminal region of
the light chain and the γ-loop. For both molecules,
clear electron density was observed for 7–8 residues
(Thr273/Asp274–Pro280) of the GpIbα peptide
at thrombin's exosite II (Fig. 3a and b). The second
structure, in slightly higher salt concentration (100 mM
sodium formate, “high salt”) and space group P21,
diffracted to 1.75 Å and was refined to Rwork/Rfree of
20.95/24.23% (Table 2). It contained four thrombin
molecules in the asymmetric unit, and aswith the other
structure, all molecules are nearly identical. However,
only 3–4 GpIbα residues (Asp274/Leu275–Asp277)
could bebuilt into electron density at thrombin's exositeII for each of the molecules, probably reflecting the
decreased affinity for GpIbα at higher salt concentra-
tions. In all six copies of thrombin, the peptide was
observed to make contact exclusively with exosite II
in spite of the 10-fold molar excess of the peptide, the
high concentrations used and the fact that exosite I is
not making crystal contacts and is therefore available
for peptide binding.
The first complex of the low-salt structure is
described here in detail because more of the GpIbα
peptide is visible in electron density (Fig. 3a and b).
The interface between thrombin and GpIbα mainly
involves charged interactions between the basic
exosite II residues (Arg93, Arg101, Arg126, Lys235,
Lys236 and Lys240) and acidic GpIbα side chains
(p-Tyr276, Asp277, p-Tyr278 and p-Tyr279). Several
hydrogen bonds are also observed between the pep-
tide backbone (carboxyl group of Asp274, Leu275
and p-Tyr276) and thrombin (side chains of Arg126
and Arg233). Additionally, Phe232 of thrombin makes
pi-stacking interactions with p-Tyr276 of the peptide
(Fig. 3c). The complementarity of the interface is
evident when the electrostatic surface of thrombin is
shown (Fig. 3d).
Fig. 4. Two-dimensional (2D) NMR spectra of thrombin with GpIbα. (a) Overlay of 2D TROSY 1H–15N NMR spectra of
free thrombin (blue) and thrombin with 0.5-fold (green), 1.1-fold (orange) and 5-fold (red) molar excess of the GpIbα
peptide. The residues with the largest chemical shift perturbation with a 1.1-fold addition of GpIbα are labelled in black.
Examples of residues with a small perturbation for 1.1-fold excess GpIbα, but a larger perturbation at 5-fold excess of
GpIbα are labelled grey. Circles indicate residues with disappearing resonances either due to exchange broadening
(indicative of changed dynamics) or due to movement of the cross-peak into a crowded region. (b) Overlay of 2D TROSY
1H–15N NMR spectra of free thrombin (blue) and thrombin with 1.1-fold molar excess (red) of the extracellular domain of
GpIbα. The residues with the highest chemical shift perturbation after addition of GpIbα are labelled in black.
886 GPIbα Interaction with ThrombinNMR chemical shift perturbation experiments
To map the footprint of the GpIbα peptide on
thrombin, we conducted NMR chemical shift pertur-
bation experiments. This method is sensitive to local
environmental changes and longer-range conforma-
tional changes caused by the binding of ligands, even
when the affinity is extremely low (Kd in the millimolarrange) [37]. The experiments with the GpIbα peptide
were based on the NMR chemical shift backbone
assignments for PPACK-thrombin that we published
in 2010 [38]. PPACK-thrombin was used to reduce
the conformational dynamics of thrombin and thus
improve the fraction of residues with resonances
assigned. PPACK binding in the active site also
reduces the allosteric linkage between the two exosites
1.1× γ’ peptide
1.1× GpIbα(1-289)
1.1× GpIbα peptide
hirugen
5× GpIbα peptide
5× γ’ peptide
a) b)
c) d)
e) f)
Fig. 5. Footprint of chemical shift perturbations plotted on the structure of thrombin. Thrombin crystal structures (heavy
chain only) are coloured according to the chemical shift perturbations after addition of the indicated ligand. Residues are
coloured from blue to orange with increasing magnitude of chemical shift perturbation. Residues whose resonances
appear or disappear after addition of the ligand are coloured red, and those that are unassigned are white. In all cases,
thrombin was inhibited by PPACK (yellow sticks) and spectra were recorded in the presence of Na+ (magenta ball).
Thrombin with a 1.1-fold excess of the GpIbα peptide (a), 5-fold excess of the GpIbα peptide (b), 1.1-fold excess of
the fibrinogen γ′-peptide (c), 5-fold excess of the fibrinogen γ′-peptide (d), 1.1-fold excess of hirugen (e) and 1.1-fold
excess of the full extracellular domain of GpIbα (f). Ligands are shown as semitransparent sticks to indicate binding
locations observed in crystal structures.
887GPIbα Interaction with Thrombinso that direct thrombin–peptide interactions are
measured without complicating the data analysis by
long-range allosteric effects. Two-dimensional 1H,15Ntransverse relaxation optimised spectroscopy
(TROSY) NMR spectra were recorded with increasing
amounts of the phosphorylated GpIbα peptide (0.5-,
a)
b)
c)
Fig. 6. Stereo views of acidic C-terminal region of
GpIbα from crystal structures. The GpIbα peptides
from various structures are shown after superposition
of the thrombin molecules. (a) The exosite II contacts for
the acidic regions (274–280) from 1P8V (green) and 1OOK
(cyan) are remarkably similar. (b) The same region as in (a),
now including the six thrombin–peptide interactions from the
structures reported here (1P8V in green and 1OOK in cyan;
molecules 1 and 2 of the low-salt structure in yellow and
magenta, respectively. The four other colours indicate the
molecules from the high-salt structure). (c) The conserved
core is composedof the Leu275-pTyr276-Asp277 tripeptide,
colours as in (b).
888 GPIbα Interaction with Thrombin1.1- and 5-fold molar ratio compared to thrombin)
(Fig. 4a). Only a small subset of resonances is
perturbed by the addition of the peptide, confirming
the specificity of the interaction between thrombin and
the peptide. Affected resonances either are shifted ordisappear after addition of the peptide, indicating
altered environment or dynamical behaviour (Fig. 4a).
The residues with perturbed resonances were
mapped onto the structure of thrombin and show
that the changes at low (1.1-fold) excess of peptide
cluster in exosite II (Fig. 5a). The largest perturbations
are observed for typical exosite II residues such
as Arg93, the regions around Arg101 and Arg126
and in the C-terminal helix (Phe232–Asp243). At a
higher peptide concentration (5-fold excess, ~0.5 mM
peptide), a few additional perturbations are detectable
for residues near exosite I (Fig. 5b). To determine
the significance of these additional perturbations,
we performed control experiments with the exosite II
ligand fibrinogen γ′-peptide (Fig. 5c and d). Com-
parison of the results with the GpIbα peptide
and the fibrinogen γ′-peptide shows that both induce
very similar chemical shift perturbations in exosite II.
At high concentrations, both peptides induce addi-
tional perturbations near exosite I (Fig. 5b versus d).
These perturbations, however, differ significantly from
those induced by the known exosite I ligand hirugen
[38] (Fig. 5e) and are likely explained by the allosteric
linkage between the two exosites. These results
suggest that the small perturbations in the vicinity of
exosite I when using a large excess (500 μM) of the
GpIbα and γ′-peptides donot reflect bona fideexosite I
interactions. This, however, still leaves open the
possibility that the LRR region of GpIbα mediates
an exosite I interaction, as found as a crystal contact in
1P8V.
To investigate this, we performed chemical shift
perturbation experiments with the extracellular domain
of GpIbα, GpIbα(1-289). Because of limited availability
and solubility of GpIbα(1-289), we were only able
to achieve a 1.1-fold excess of the ligand. The NMR
TROSY heteronuclear single quantum correlation
spectrum was comparable in quality to that recorded
with the peptide ligand (Fig. 4b), and a further
TROSY HNCA experiment was run to help re-assign
the perturbed resonances. As before, only a specific
subset of thrombin resonances is affected by addition
of the ligand (Fig. 4b). Mapping the chemical shift
perturbations onto the structure of thrombin reveals
a very similar pattern to what was observed for
the isolated acidic peptide (Fig. 5f). Themain changes
centre on exosite II, including residues around
Arg93 (Ile88, Tyr89, Tyr94), Arg126 (Leu123,
Tyr129–Ser129b) and the C-terminal helix (Phe232–
Asp243), with a few changes near exosite I. No new
perturbations are visible, suggesting that the LRR
region does not contribute to the binding of thrombin.
In addition, one-dimensional relaxation measure-
ments indicated a 1:1 complex of PPACK-thrombin
and GpIbα(1-289), with an apparent molecular
mass of 67 kDa, ruling out the possibility of the
presence of higher-order complexes. The weighted
chemical shift differences for all experiments are
given in Supplementary Table 1.
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It is not possible to review every experiment
ever conducted regarding the binding site of GpIbα
on thrombin within this manuscript. The attention
this issue has received reflects the importance of
thrombin and platelets in physiological and patho-
logical blood clotting. Suffice it to say that there is a
plethora of biochemical and structural data concern-
ing the GpIbα–thrombin interaction, some experi-
ments properly designed, conducted and interpreted
and others that require closer examination. The goal
of this work is to see if, by using simple and sensitive
biophysical and structural methods, we can clear up
the mechanistic controversy that seems to be deeply
entrenched regarding the role of exosite I in GpIbα
binding.
It is useful to step back and review what we really
know about the interaction between thrombin and
GpIbα. Firstly, GpIbα is the high-affinity thrombin
receptor on platelets, and the interaction is mediated
by the C-terminal acidic region of the extracellular
domain. The interaction results in a 1:1 complex that
can be purified as such by size-exclusion chroma-
tography, even at high concentrations and with an
excess of thrombin. It is also accepted that, at least in
solution, the principal interaction site for the acidic
region of GpIbα is exosite II of thrombin. Several
reports employing competition with various “exosite-
specific” ligands have also implicated exosite I, and
these reports were used to interpret the two crystal
structures of the thrombin–GpIbα complex that were
published in 2003. At first glance, it is remarkable that
the two structures were so very different, since it is
reasonable to expect that the important interactions
allowing both groups to purify a 1:1 complex would
be preserved. Indeed, the exosite II interactions
are remarkably similar (Fig. 6a), while the exosite I
interactions are completely different, one binding to
the opposite side of the acidic peptide and another
binding to the LRR domain (see Fig. 1c and d). The
six exosite II contacts with the acidic peptide observed
in our crystal structures are also very similar to
the contacts seen in the first two structures (Fig. 6b).
Indeed, there is a remarkable conservation of
structure and interactions in a core three-residue
motif, 275LY⁎D277 (Y⁎ indicating phosphorylated or
sulfated tyrosine), in all eight structures (Fig. 6c). The
variability seen in the flanking regions likely reflects
the non-directional nature of ionic interactions and
the different environments (crystal contacts) in the
various crystals. With the simple and reasonable
assumption that important contacts will be preserved
in all structures, we can conclude that the binding of
the 275LY⁎D277 motif of GpIbα to exosite II of thrombin
is the core interaction, in good agreement with
previously published NMR data that identified resi-
dues D274–Y279 as critical for thrombin binding [31].
Wealso know that the acidic region ofGpIbα is flexiblerelative to the LRR domain. This is evident not only
from the two crystal structures of GpIbα with thrombin
but also from the other nine structures of the same
construct of GpIbα (two copies each for 1GWB [9],
1M0Z [39] and 1QYY [40]; one copy each for 1P9A,
1M10 [39] and 1SQ0 [41]). The acidic C-terminal tail
can only be placed in electron density of one of these
nine structures (1GWB, chain B), and in that case,
it was making extensive contacts with the other copy
of GpIbα in the asymmetric unit. Indeed, this lone
copy of GpIbα is the structure used to hypothesise a
“conformational change” in the C-terminus to allow
binding via exosite I [34]. Finally, we know that crystals
cannot form without crystal contacts. This means that
there will always be interactions that help to stabilise
the crystal lattice but do not reflect physiologically
relevant protein–protein interactions. Accommodating
thrombin in a crystal lattice requires compensating for
its two large electrostatically positive exosites, and
in 1OOK, this is likely what happened, with the acidic
peptide interposing between exosites I and II. There
is no evidence that such a bivalent interaction
happens in solution. In fact, if it did, thrombin would
aggregate in the presence of solubleGpIbα, rendering
it impossible to purify the 1:1 complex by size-
exclusion chromatography, and precluding NMR
studies.
It has been argued that the bivalent interaction
involving thrombin exosites I and II requires a surface,
such as that of a platelet membrane or an SPR chip
[32]. Here we show that, on a surface (Octet Red tip),
thrombin binds to the acidic GpIbα peptide exclusively
with exosite II. This was performed using single charge
reversal mutations instead of competition; thus, the
data are not affected by any lack of specificity of
the competing ligand. However, we did not conduct the
binding studies using the full-length GpIbα construct;
thus, the possibility still remained that the LRR region
couldmediate further interactions. Thiswasaddressed
using the sensitive technique of NMR spectroscopy.
We found that an excess of peptide and full-length
GpIbα at ~100 μM thrombin did not perturb reso-
nances in exosite I, and when plotted on the structure
of thrombin, the effects were essentially identical
with those obtained with the exosite-II-specific ligand,
fibrinogen γ′. The peptide-binding interface identified in
the NMR experiments is larger than that observed
in the crystal structures, likely reflecting the fact that
the GpIbα peptide is longer than the maximum
of 8 residues observed in the crystal structures and
that NMR spectroscopy is able to identify weak and
transient interactions and long-range structural pertur-
bations. The chemical shift perturbations close to
exosite I observed for both the fibrinogen γ′-peptide
and the GpIbα peptide were also identified in a recent
H/D exchange study [31] and were explained by
allosteric linkage between the two exosites, as has
been suggested by some researchers [42] or by non-
specific binding to exosite I at high concentrations.
890 GPIbα Interaction with ThrombinThe NMR experiments with the extracellular domain
of GpIbα confirm the exosite II interaction but do not
indicate any additional interactions of the LRR with
thrombin's exosite I. This again is in agreement with
a recent H/D exchange study [31]. It should be noted
that NMR is capable of detecting interactions with Kd
values in the millimolar range. Our data therefore
argue strongly against any exosite I interaction with
GpIbα in solution.
Taken together, our experiments add to a large
body of data to show that GpIbα binds exclusively
to thrombin's exosite II. This binding mode does
not allow any additional non-catalytic function of
thrombin on platelets, such as receptor cross-linking
or platelet adhesion. Instead, GpIbα binding localises
thrombin activity to the platelet surface, and by
utilising exosite II for GpIbα binding, thrombin is
free to engage PAR-1 and other substrates dependent
on exosite I.Materials and Methods
Proteins and peptidesWild-type thrombin was expressed in BL21Star(DE3)
pLysS Escherichia coli as prethrombin-2 in inclusion
bodies, re-solubilised, refolded and purified using heparin
Sepharose (GE healthcare), as described previously [43].
It was activated with PMSF-treated Echis carinatus venom
for 1 h at 37 °C and inhibited with a 5-fold molar excess of
PPACK for 30 min at room temperature. PPACK-thrombin
was repurified with heparin-Sepharose. Thrombin mutants
were generated using the QuikChange site-directed
mutagenesis kit (Stratagene) with pET23-prethrombin-2
(S195A) as template. The GpIbα peptide (Ac-
Gly268-Thr284-NH2), N-terminally biotin-labelled GpIbα
peptide (biotin-Gly268-Thr284-NH2), the PAR-1 peptide
(Ac-Ser16-Asn36-NH2) and the fibrinogen γ′-peptide
(Ac-Val408-Leu427) were synthesised by Peptide Protein
Research Ltd. (Fareham, UK). All peptides contained
phosphorylated tyrosine residues instead of the naturally
occurring sulfotyrosine. This is not expected to affect
binding to thrombin [44,45]. Hirugen (hirudin Gly54-Gln65)
was purchased from Sigma or Cambridge Bioscience
(Cambridge, UK). Fragment-2 was generated from
plasma-derived prothrombin using human fXa (Haemato-
logic Technologies). The GpIbα(1-289)-calmodulin fusion
protein was a kind gift from Willem Ouwehand (Depart-
ment of Haematology, University of Cambridge) and was
expressed in Sf9 cells as previously described [46]. GpIbα
was cleaved from calmodulin using porcine pancreatic
elastase (1:60, w/w) in phosphate-buffered saline over-
night, and GpIbα was separated from calmodulin using
anion-exchange chromatography equilibrated in 20 mM
Tris (pH 8) and 50 mM NaCl. Proteins were eluted
with a NaCl gradient from 50 to 1000 mM over 10
column volumes. The PAR-1 peptide and fragment-2
were biotin-labelled using the EZ-Link NHS polyethyl-
ene glycol (PEG)-4 biotin kit (Thermo Scientific) with
the protocol for preferential labelling of the N-terminus [47].Binding assays
All experiments were performed in 20 mM Hepes
(pH 7.4), 150 mM NaCl, 5 mM CaCl2, 0.1 mg/ml bovine
serum albumin and 0.002% Tween20 (binding buffer)
on an Octet RED instrument (fortéBIO) with streptavidin
biosensors. Biotin-labelled peptides were loaded onto
the biosensors at 1 μg/ml, and the biotin-fragment-2 was
loaded at 5 μg/ml. S195A thrombin control and exosite
variants were diluted in binding buffer with concentrations
between 0.15 and 40 μM. Data traces were analysed
using fortéBIO Analysis software and Prism (GraphPad).
Steady-state responses were plotted versus concentration
and fit to a 1:1 specific binding model to obtain dissociation
constants (Kd).
Crystallisation
PPACK-inhibited thrombin (4.6 mg/ml) in 20 mM Tris
(pH 7.4) and 100 mM NaCl was added to a 10-fold molar
excess of lyophilised GpIbα peptide. Initial screens were
set up in MRC 96-well plates using the sitting-drop vapour
diffusion method with 200 nl protein solution and 200 nl
reservoir solution. Crystals appeared after 3–4 days in
100 mM sodium formate and 12% (w/w) PEG-3350 and
were optimised using a hanging-drop vapour diffusion
grid screen with 1 μl + 1 μl drops. After 2 days, crystals
from two conditions were harvested. Condition 1 contained
50 mM sodium formate and 16% PEG-3350, and condition
2 contained 100 mM sodium formate and 18% PEG-3350.
Crystals from both conditions were cryoprotected in
100 mM sodium formate and 18% PEG-3350 and increas-
ing amounts of glycerol up to 20% and were cryo-cooled in
liquid nitrogen. Data were collected at 100 K on beamline
I03 at Diamond Light Source (Didcot, UK). Diffraction
markedly improved after annealing by blocking the cryo-
stream three times for 3 s. Data were processed using
Mosflm, Scala and Truncate [48] from the CCP4 [49]
package, and structures were solved by molecular
replacement using Phaser [50] with chains A and B from
structure 1JOU [51] as search model. Rebuilding and
refinement were conducted using Coot [52] and Refmac
[53]. All figures were produced with PyMOL [54]. Crystal-
lographic data for the two structures are given in Table 2,
and the coordinates and structure factors have been
deposited in the Protein Data Bank under accession codes
4ch2 and 4ch8.
NMR spectroscopy
For NMR spectroscopy, 2H, 13C, 15N-labelled prethrom-
bin-2 was expressed, purified and activated as described
previously [38]. PPACK-inhibited wild-type thrombin at a
concentration of 80–100 μM in 50 mM sodium phosphate
(pH 7.4), 5% D2O and 0.02% NaN3 was used for all NMR
experiments. Increasing amounts of the GpIbα peptide
or the fibrinogen γ′-peptide were added to the NMR
sample fromhighly concentrated stock solutions tominimise
sample dilution. For experiments with GpIbα(1-289), the
protein was added to a thrombin solution at 1.1-fold
excess and then concentrated and dialysed into NMR
buffer. A TROSY-based HNCA experiment was measured
to re-assign the shifted resonances. All NMR spectra were
891GPIbα Interaction with Thrombinrecorded on a Bruker Avance II+ 700-MHz spectrometer
with a TCI triple resonance cryoprobe at 37 °C, processed in
TopSpin 2.1 (Bruker) and analysed in Sparky (University
of California, San Francisco). Weighted chemical shift per-
turbations [55] were calculated with Δδ(1H) + Δδ(15N)/5.
Assignments for the reference spectrum of unliganded
PPACK-thrombin and PPACK-thrombin with hirugen
were taken from our previous work [38]. The molecular
weight of the thrombin–GpIbα(1-289) NMR sample
was estimated using a 1H T2 relaxation experiment
based on the Hahn spin-echo pulse sequence [56] with
relaxation delays of 2 and 0.4 ms. The T2 relaxation
time is determined by the rate of signal attenuation
during the two relaxation delays. From this, the rotational
correlation time τc can be determined [τc ≈ 1/(5T2) ns,
where T2 is expressed in seconds] [57]; τc in turn
is directly proportional to the molecular weight of the
sample.
Accession numbers
The atomic coordinates and structure factors have
been deposited in the PDB under accession codes 4ch2
and 4ch8.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jmb.2013.11.027.Acknowledgements
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